Các yếu tố xã hội-dân số, lâm sàng, tâm lý-xã hội và liên quan đến chăm sóc sức khỏe ảnh hưởng đến niềm tin về liệu pháp nội tiết hỗ trợ ở những người sống sót sau ung thư vú

American Cancer Society (2019) Breast Cancer Facts & Figures, in American Cancer Society I (ed). Atlanta. Alkner S, Bendahl PO, Ferno M, Nordenskjold B, Ryden L, South S, South-East Swedish Breast Cancer G (2009) Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur J Cancer 45(14):2496–2502. https://doi.org/10.1016/j.ejca.2009.05.022 Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8 Arimidex TAoiCTG, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45–53 Early Breast Cancer Trialists’ Collaborative Group E (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717 Livaudais JC, Lacroix A, Chlebowski RT, Li CI, Habel LA, Simon MS, Thompson B, Erwin DO, Hubbell FA, Coronado GD (2013) Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women’s health initiative. Cancer Epidemiol Biomark Prev 22(3):365–373. https://doi.org/10.1158/1055-9965.Epi-12-1225 Farias AJ, Du XL (2016) Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare part D. Med Oncol 33(2):19-016-0732-0731. https://doi.org/10.1007/s12032-016-0732-1 Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478. https://doi.org/10.1007/s10549-012-2114-5 Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128. https://doi.org/10.1200/JCO.2009.25.9655 Hurtado-de-Mendoza A, Jensen RE, Jennings Y, Sheppard VB (2018) Understanding breast cancer survivors’ beliefs and concerns about adjuvant hormonal therapy: promoting adherence. J Cancer Educ 33(2):436–439. https://doi.org/10.1007/s13187-017-1180-0 Tan X, Camacho F, Marshall VD, Donohoe J, Anderson RT, Balkrishnan R (2017) Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer. Res Social Adm Pharm 13(4):796–810. https://doi.org/10.1016/j.sapharm.2016.08.004 Hershman DL, Kushi LH, Hillyer GC, Coromilas E, Buono D, Lamerato L, Bovbjerg DH, Mandelblatt JS, Tsai WY, Zhong X, Jacobson JS, Wright JD, Neugut AI (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 157(1):133–143. https://doi.org/10.1007/s10549-016-3788-x Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD (2017) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence 11:305–322. https://doi.org/10.2147/PPA.S126651 Qvarnstrom M, Kahan T, Kieler H, Brandt L, Hasselstrom J, Wettermark B (2019) Medication persistence to antihypertensive drug treatment - a cross-sectional study of attitudes towards hypertension and medication in persistent and non-persistent patients. Blood Press 1–8. https://doi.org/10.1080/08037051.2019.1627858 Al-Noumani H, Wu JR, Barksdale D, Alkhasawneh E, Knafl G, Sherwood G (2017) Relationship between medication adherence and health beliefs among patients with hypertension in Oman: pilot study. Sultan Qaboos Univ Med J 17(3):e329–e333. https://doi.org/10.18295/squmj.2017.17.03.012 Kadakia KC, Kidwell KM, Barton DL, Schott AF, Hayes DF, Griggs JJ, Henry NL (2019) Factors influencing the use of extended adjuvant endocrine therapy. Breast Cancer Res Treat 175:181–189. https://doi.org/10.1007/s10549-019-05145-8 Thorneloe RJ, Horne R, Side L, Wolf MS, Smith SG (2019) Beliefs about medication and uptake of preventive therapy in women at increased risk of breast cancer: results from a multicenter prospective study. Clin Breast Cancer 19(1):e116–e126. https://doi.org/10.1016/j.clbc.2018.10.008 Bright EE, Petrie KJ, Partridge AH, Stanton AL (2016) Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat 158(2):243–251. https://doi.org/10.1007/s10549-016-3871-3 Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145(2):525–534. https://doi.org/10.1007/s10549-014-2961-3 Brett J, Fenlon D, Boulton M, Hulbert-Williams NJ, Walter FM, Donnelly P, Lavery B, Morgan A, Morris C, Watson E (2018) Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care (Engl) 27(1). https://doi.org/10.1111/ecc.12601 Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438. https://doi.org/10.1200/jco.18.01160 Salgado TM, Davis EJ, Farris KB, Fawaz S, Batra P, Henry NL (2017) Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. Breast Cancer Res Treat 163(2):311–319. https://doi.org/10.1007/s10549-017-4177-9 Kumar K, Gordon C, Barry R, Shaw K, Horne R, Raza K (2011) It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in rheumatoid arthritis and systemic lupus erythematosus patients of South Asian origin. Lupus 20(8):837–844. https://doi.org/10.1177/0961203311398512 Sheppard VB, Hurtado-de-Mendoza A, Zheng YL, Wang Y, Graves KD, Lobo T, Xu H, Jennings Y, Tolsma D, Trout M, Robinson BE, McKinnon B, Tadesse M (2018) Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine. J Cancer Surviv 12(1):74–81. https://doi.org/10.1007/s11764-017-0646-8 Pellegrini I, Sarradon-Eck A, Ben Soussan P, Lacour AC, Largillier R, Tallet A, Tarpin C, Julian-Reynier C (2010) Women’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view. Psychooncology 19(5): 472479. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55(2):189–199 Wolf MS, Chang CH, Davis T, Makoul G (2005) Development and validation of the communication and attitudinal self-efficacy scale for cancer (CASE-cancer). Patient Educ Couns 57(3):333–341 Lukwago SN, Kreuter MW, Bucholtz DC, Holt CL, Clark EM (2001) Development and validation of brief scales to measure collectivism, religiosity, racial pride, and time orientation in urban African American women. Fam Community Health 24(3):63–71 Bird ST, Bogart LM (2001) Perceived race-based and socioeconomic status(SES)-based discrimination in interactions with health care providers. Ethn Dis 11(3):554–563 Sherbourne CD, Stewart AL (1991) The MOS social support survey. Soc Sci Med 32(6):705–714 National comprehensive cancer network: NCCN clinical practice guidelines in oncology v. 2 (2008) Marshall G, Hays RD (1994) The patient satisfaction questionnaire short-form (PSQ-18), P-7865. Vol book, whole Makoul G (2003) The interplay between education and research about patient-provider communication. Patient Educ Couns 50(1):79–84 Safran DG, Kosinski M, Tarlov AR, Rogers WH, Taira DH, Lieberman N, Ware JE (1998) The primary care assessment survey: tests of data quality and measurement performance. Med Care 36(5):728–739 LaVeist TA, Isaac LA, Williams KP (2009) Mistrust of health care organizations is associated with underutilization of health services. Health Serv Res 44(6):2093–2105. https://doi.org/10.1111/j.1475-6773.2009.01017.x Wuensch P, Hahne A, Haidinger R, Meissler K, Tenter B, Stoll C, Senf B, Huebner J (2015) Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol 141(1):55–60. https://doi.org/10.1007/s00432-014-1779-z Kamal S, Bugnon O, Cavassini M, Schneider MP (2018) HIV-infected patients’ beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy. HIV Med 19(1):49–58. https://doi.org/10.1111/hiv.12542 Brett J, Boulton M, Fenlon D, Hulbert-Williams NJ, Walter FM, Donnelly P, Lavery BA, Morgan A, Morris C, Watson EK (2018) Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence 12:291–300. https://doi.org/10.2147/ppa.S145784 Farias AJ, Ornelas IJ, Hohl SD, Zeliadt SB, Hansen RN, Li CI, Thompson B (2017) Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. Support Care Cancer 25(1):75–83. https://doi.org/10.1007/s00520-016-3389-6 Badanta-Romero B, de Diego-Cordero R, Rivilla-Garcia E (2018) Influence of religious and spiritual elements on adherence to pharmacological treatment. J Relig Health 57(5):1905–1917. https://doi.org/10.1007/s10943-018-0606-2 Vyas KJ, Limneos J, Qin H, Mathews WC (2014) Assessing baseline religious practices and beliefs to predict adherence to highly active antiretroviral therapy among HIV-infected persons. AIDS Care 26(8):983–987. https://doi.org/10.1080/09540121.2014.882486 National Collaborating Centre for Primary Care (UK) (2009) Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence. Royal College of General Practitioners (UK), London.